Ticagrelor 60 vs. 90 mg in Elderly ACS Patients undergoing PCI: a Randomized, Crossover Trial.
Raffaele PiccoloFiorenzo SimonettiMarisa AvvedimentoMaria CutilloMario Enrico CanonicoValeria ContiGiuseppe GargiuloRoberta PaolilloFabrizio Dal PiazAmelia FilippelliBruno CharlierAlessandra SpinelliStefano CristianoPlinio CirilloLuigi Di SerafinoAnna FranzoneGiovanni EspositoPublished in: European heart journal. Cardiovascular pharmacotherapy (2024)
Although plasma concentrations were lower, ticagrelor 60 mg twice daily provided a similar magnitude of platelet inhibition compared with ticagrelor 90 mg twice daily among elderly patients undergoing PCI. Clinical Trial registration: EudraCT 2019-002391-13. Clinicaltrials.gov NCT04739384.
Keyphrases
- acute coronary syndrome
- patients undergoing
- percutaneous coronary intervention
- antiplatelet therapy
- clinical trial
- st elevation myocardial infarction
- st segment elevation myocardial infarction
- acute myocardial infarction
- phase ii
- open label
- middle aged
- study protocol
- phase iii
- coronary artery disease
- physical activity
- double blind
- coronary artery bypass grafting
- community dwelling
- randomized controlled trial
- atrial fibrillation
- placebo controlled
- heart failure
- coronary artery bypass